Actively Recruiting
Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma
Led by West China Hospital · Updated on 2024-05-07
50
Participants Needed
1
Research Sites
269 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
CONDITIONS
Official Title
Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children with superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)
You will not qualify if you...
- Hypersensitivity to Tacrolimus mucosal Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
Y
Yi Ji, PHD, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here